๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Triple Negative Breast Cancer
Clinical trial register · China

Triple Negative Breast Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 15 Guangzhou 13 Beijing 12 Harbin 5 Chongqing 4
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University10 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University3 Sichuan Baili Pharmaceutical Co., Ltd.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2 Hebei Medical University Fourth Hospital2
Site location
Shanghai15 Guangzhou13 Beijing12 Harbin5 Chongqing4
All 32 locations
Target enrolment
to

Triple Negative Breast Cancer trials in China

48 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
NCT07679360Triple Negative Breast Cancer
DrugsTrastuzumab Rezetecan·Adebrelimab·Capecitabine·Pembrolizumab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
1,000
Beijing
2026-09-02
Recruiting
Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
NCT07739485Triple -Negative Breast Cancer
Liu Shu
Phase 1/2
30
Guiyang
2026-07-30
Recruiting
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
NCT07533123Triple Negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
364
Guangzhou
2026-03-17
Recruiting
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
NCT07283692Triple Negative Breast Cancer
DrugsSerplulimab·Carboplatin·Paclitaxel
RenJi Hospital
Phase 2
46
Shanghai
2026-03-01
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
NCT07510802Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Not yet open
Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
NCT07419880Triple -Negative Breast Cancer
Fudan University
Phase 2
46
Shanghai
2026-01-30
Recruiting
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
NCT07281976Triple Negative Breast Cancer
DrugsLBL-024·Albumin-Bound Paclitaxel·Tislelizumab
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
220
Guangzhou, Harbin, Zhengzhou, Nanjing, Changchun, Shenyang
2026-01-27
Recruiting
Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
NCT07401537Triple -Negative Breast Cancer, Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
416
Guangzhou
2025-12-31
Recruiting
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311Triple-negative Breast Cancer
Drugs9MW2821·JS207·Albumin paclitaxel
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Not yet open
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
NCT07139470Triple Negative Breast Cancer
DrugsAnlotinib·Sacituzumab tirumotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
59
Tianjin
2025-08-15
Recruiting
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
NCT07705438Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT
Fudan University
Observational
30
Shanghai
2025-05-28
Recruiting
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
NCT06889688Breast Cancer Stage IV, Triple -Negative Breast Cancer
DrugsEribulin·Apatinib·Tislelizumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
246
Guangzhou, Guiyang, Wuhan, Yichang, Changsha, Yongzhou, Shanghai
2025-02-21
Recruiting
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
NCT06817525Triple-negative Breast Cancer
Henan Cancer Hospital
Phase 2
64
Zhengzhou
2024-11-06
Recruiting
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
NCT06371274Triple-negative Breast Cancer
DrugsATRA·Tislelizumab
First Affiliated Hospital of Zhejiang University
Not applicable
29
Hangzhou
2024-10-10
Recruiting
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis๏ผŒan Exploratory, Single-Arm, Multicenter Phase II Clinical Study
NCT06538896Triple-negative Breast Cancer, Bone Metastases
DrugsNab-paclitaxel·Tislelizumab
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou
2024-08-20
Active, closed
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
NCT06519370Triple Negative Breast Cancer
DrugsVinorelbine·Eribulin·Capecitabine·Gemcitabine
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 3
350
Shanghai
2024-08-09
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
NCT06471205Triple-negative Breast Cancer
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2024-08-02
Recruiting
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
NCT06533384Triple-negative Breast Cancer
DrugCapecitabine
Guangdong Provincial People's Hospital
Phase 3
310
Guangzhou
2024-08-01
Recruiting
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT06492005Triple-Negative Breast Cancer
DrugsPD-1 inhibitior·9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
160
Shanghai
2024-07-26
Active, closed
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
NCT06382142Triple-Negative Breast Cancer
DrugsVinorelbine·Eribulin·Iza-bren·Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
418
Shanghai
2024-06-21
Recruiting
Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
NCT06367088Triple-negative Breast Cancer, Cadonilimab
DrugCadonilimab
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
27
Wuhan
2024-05-01
Recruiting
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
NCT06279364Triple Negative Breast Cancer
DrugsEribulin·Sacituzumab tirumotecan·Nab-paclitaxel·Capecitabine
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
524
Shanghai
2024-02-28
Not yet open
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
NCT06202313Triple Negative Breast Cancer
DrugsEribulin·Cadonilimab
Shengjing Hospital
Phase 2
128
Shenyang
2024-02-10
Recruiting
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332Breast Cancer, Triple Negative Breast Cancer
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Active, closed
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT07018427Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Breast Cancer
Peking University Cancer Hospital & Institute
Observational
70
Beijing
2023-05-01
Recruiting
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05806060Triple-Negative Breast Cancer
Fudan University
Phase 3
134
Shanghai
2023-04-25
Recruiting
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
NCT05749588Triple-negative Breast Cancer
Fudan University
Phase 2
120
Shanghai
2023-03-30
Recruiting
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
NCT05760378Triple-Negative Breast Cancer
DrugsFamitinib·Tislelizumab
Fudan University
Phase 3
223
Shanghai
2023-03-17
Recruiting
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
NCT05475678Breast Cancer, Triple Negative Breast Cancer, Camrelizumab
DrugCarrelizumab
Zhenzhen Liu
Phase 2
369
Zhengzhou
2022-12-20
Recruiting
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
NCT05447702Triple Negative Breast Cancer
DrugsEpirubicin·Apatinib·Nab-paclitaxel·Cyclophosphamide
West China Hospital
Phase 2
35
Chengdu
2022-11-01
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
DrugsSacituzumab Govitecan·Nab-paclitaxel·Gemcitabine·Carboplatin
Gilead Sciences
Phase 3
623
Beijing, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou, Harbin
2022-07-20
Active, closed
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
NCT05460273Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer
DrugsDatopotamab deruxtecan·Dato-DXd
AstraZeneca
Phase 1/2
119
Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-07-11
Recruiting
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682Triple-negative Breast Cancer
DrugsAK131·Efavirenz·Mecapegfilgrastim·SHR-A2102
Fudan University
Phase 2
80
Shanghai
2022-06-30
Active, closed
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
NCT05347134Triple Negative Breast Cancer
DrugSacituzumab tirumotecan
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
254
Beijing, Nanjing
2022-06-10
Recruiting
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
NCT05192798Triple-negative Breast Cancer
DrugsApatinib Mesylate·Albumin-Bound Paclitaxel·Bevacizumab
The First Affiliated Hospital of Bengbu Medical University
Phase 2
128
Bengbu
2022-01-14
Active, closed
Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)
NCT06618014Breast Cancer, Triple Negative Breast Cancer
DrugsCarboplatin·Paclitaxel·Tislelizumab
Sun Yat-sen University
Phase 2
51
Guangzhou
2022-01-11
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Recruiting
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
NCT04722978Triple Negative Breast Cancer
DrugMoxifloxacin
Sun Yat-Sen University Cancer Center
Phase 3
228
Guangzhou
2021-04-20
Recruiting
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
NCT04501523Triple-negative Breast Cancer
DrugsCapecitabine·Tislelizumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
460
Guandong
2020-08-03
Recruiting
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
NCT04481763Triple-Negative Breast Cancer
DrugTislelizumab
Jiangxi Provincial Cancer Hospital
Phase 1/2
20
Nanchang
2020-07-14
Active, closed
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)
NCT04296175Triple-negative Breast Cancer
DrugsCarbo·Epirubicin·Carboplatin·Paclitaxel
Fudan University
Phase 3
808
Shanghai
2020-03-05
Recruiting
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
NCT04437160Triple Negative Breast Cancer
Chinese Academy of Medical Sciences
Phase 2
286
Beijing
2020-02-01
Recruiting
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
NCT04138719Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel
DrugsEpirubicin·Nab-paclitaxel·Carboplatin
Hebei Medical University Fourth Hospital
Phase 2
520
Shijiazhuang
2019-11-20
Recruiting
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
NCT04159142Triple Negative Breast Cancer, Nab-paclitaxel
DrugsNab-paclitaxel·Capecitabine·Carboplatin
Hebei Medical University Fourth Hospital
Phase 2
414
Shijiazhuang
2019-11-20
Recruiting
Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
NCT06700382Triple Negative Breast Cancer
DrugCapecitabine
Shu Wang
Observational
1,166
Beijing
2019-01-01
Recruiting
De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
NCT06692725Triple Negative Breast Cancer
Peking University People's Hospital
Observational
380
Beijing
2019-01-01
Active, closed
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT03562637Triple Negative Breast Cancer
OBI Pharma, Inc
Phase 3
575
Beijing, Guangzhou, Nanning, Harbin, Wuhan, Changsha, Nanjing, Changchun
2018-12-05
Active, closed
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
NCT02641847Triple Negative Breast Cancer, Breast Cancer
DrugsEpirubicin·Doxorubicin·Cyclophosphamide·Gemcitabine
Fudan University
Phase 2/3
503
Shanghai
2016-01
Rows per page Showing 1–48 of 48
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/triple-negative-breast-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 48 of those studies listing the condition Triple Negative Breast Cancer.

How many Triple Negative Breast Cancer trials are recruiting in China?

35 of the 48 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Triple Negative Breast Cancer), 48 studies
PhaseStudiesRecruitingShare
Phase 2201741.7%
Phase 315931.3%
Phase 1/26412.5%
Observational438.3%
Not applicable112.1%
Phase 2/3102.1%
Phase 4112.1%

Most active sponsors

Lead sponsors with the most studies (Triple Negative Breast Cancer)
Lead sponsorStudiesRecruiting
Fudan University107
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University33
Hebei Medical University Fourth Hospital22
Sichuan Baili Pharmaceutical Co., Ltd.21
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.21
AstraZeneca10
Beijing Biotech11
Chinese Academy of Medical Sciences11
First Affiliated Hospital of Zhejiang University11
Gilead Sciences10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.